MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: MR-guided adaptive radiotherapy (MGART) with reduced PTV margins, including 5 times 6Gy to the vaginal vault and pelvic nodal areas, 2 times a week.
- Who it may be relevant to
- Registry conditions: Endometrial Cancer, Radiotherapy, Adjuvant. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer (MASTEC)
Overview
Rationale: External beam radiotherapy (EBRT) is an important cornerstone in treatment to reduce locoregional relapse in high(-intermediate) risk endometrial cancer (EC) patients. MR-guided adaptive radiotherapy (MGART) allows for more accurate delivery of radiation beams to the patients by visualizing and correcting for interfraction motion, with subsequent reduction of safety margins around the radiotherapy plan. Objective: The MASTEC study will investigate the safety of hypofractionated MR-guided adaptive radiotherapy in five fractions for elective pelvic nodal and vaginal vault irradiation in endometrial cancer. Study design: Phase II multicentre intervention study Study population: Patients with endometrial cancer that receive adjuvant EBRT to the pelvic nodal areas and vaginal vault (with or without vaginal brachytherapy). Intervention (if applicable): MR-guided adaptive radiotherapy (MGART) with reduced PTV margins, including 5 times 6Gy to the vaginal vault and pelvic nodal areas, 2 times a week . Main study parameters/endpoints: The primary endpoint is acute gastrointestinal and genitourinary toxicity, scored by the Common Terminology Criteria Adverse Events version 6.0. Secondary endpoints are late gastrointestinal and genitourinary toxicity, quality of life and disease free survival; disease-specific survival; overall survival and metastasis-free survival.
Interventions
- Radiation MR-guided adaptive radiotherapy (MGART) with reduced PTV margins, including 5 times 6Gy to the vaginal vault and pelvic nodal areas, 2 times a week
Patients will be treated with hypofractionated MR-guided adaptive radiotherapy up to 30Gy to the vaginal vault and pelvic nodal areas, contoured on T2W MRI and CT (slice thickness 3mm). Radiotherapy will not be performed on consecutive days. Radiotherapy will be performed by IMRT (7MV) on an MR-linac (Elekta Unity).
Primary outcome measures
- Acute gastrointestinal and genitourinary toxicity (within 3 months after start of treatment) [Time frame: 5 years after end of treatment]
Eligibility criteria
Inclusion criteria
In order to be eligible to participate in this study, a participant must meet all of the following criteria:
- Women aged 18 years or older with histologically proven carcinoma of the endometrium, treated with curative hysterectomy with or without bilateral salpingo-oophorectomy. All histologies may be included (endometrioid, clear cell carcinoma, de-/undifferentiated carcinoma, carcinosarcoma, other non-endometrioid)
- Candidate for adjuvant EBRT as decided by multidisciplinary tumour board, amongst others:
- FIGO IB grade 3 endometrioid carcinoma
- FIGO stage II endometrioid carcinoma
- FIGO stage IIIA-C1 endometrioid carcinoma
- FIGO IB-II clear cell carcinoma
- FIGO IA-III carcinosarcioma
- Patients receiving adjuvant systemic therapy are eligible when these therapies will not be administered concurrently
- Patients receiving vaginal vault brachytherapy are eligible
- Capable of giving informed consent
Exclusion criteria
A potential participant who meets any of the following criteria will be excluded from participation in this study:
- Contra-indications for MRI according to the guidelines of the local department of Radiology, inability to lay on a treatment table for 45-60 minutes or severe claustrofobia
- Presence of para-aortic lymph node metastases (FIGO stage IIIC2)
- Prior pelvic radiotherapy
- WHO performance score > 2
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07514325 · NL-011073 · NL-011073